MSU
SUPN icon

Mizuho Securities USA’s Supernus Pharmaceuticals SUPN Stock Holding History

Mizuho Securities USA’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-12,000
Closed -$399K – 137
2018
Q4 		$399K Buy
12,000
+400
+3% +$17.2K 0.05% 99
2018
Q3 		$584K Buy
+11,600
New +$573K 0.04% 115

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
NPIC
Neumeier Poma Investment Counsel Carmel, California $1.21B AUM 70.48% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Mizuho Securities USA's SUPN Position: Q1 2019 in Review

Mizuho Securities USA sold out of Supernus Pharmaceuticals (SUPN) in Q1 2019, closing a stake of 12,000 shares — an estimated $399K sold.

Mizuho Securities USA first reported a position in SUPN in Q3 2018 and held it in 2 quarters. The position peaked at $584K in Q3 2018. 289 funds tracked by Wall St. Rank hold SUPN as of Q1 2019.

  • Mizuho Securities USA reported no remaining Supernus Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Mizuho Securities USA sold 12,000 Supernus Pharmaceuticals shares in Q1 2019, an estimated $399K.
  • Mizuho Securities USA first reported a position in Supernus Pharmaceuticals in Q3 2018 and held it in 2 quarters.
  • Mizuho Securities USA's Supernus Pharmaceuticals position peaked at $584K in Q3 2018.
  • 289 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2019.

Based on Mizuho Securities USA's 13F filing for Q1 2019, filed 24 Apr 2019.